Literature DB >> 2559072

Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils.

M T Labro1, J el Benna, C Babin-Chevaye.   

Abstract

We have compared the in-vitro interaction of five macrolides (roxithromycin, erythromycin, spiramycin, oleandomycin and josamycin) with human neutrophils (PMN). Only roxithromycin strongly impaired the oxidative burst of PMN assessed by luminol amplified chemiluminescence, superoxide anion generation, and myeloperoxidase-mediated iodination of proteins. This effect was observed only for high concentrations of this drug (100 and 50 mg/l). Furthermore, the sensitivity of PMN to the depressive effect of roxithromycin permitted the definition of two kinds of PMN: in Highly Sensitive (HS)-PMN, the oxidative response was completely abolished while in Moderately Sensitive (MS)-PMN, a decreased, but yet measurable (20-50% of the control), response was obtained. The roxithromycin-induced depression of PMN was time-dependent and partly reversed by washing. Chemotaxis was also impaired by roxithromycin (100 mg/l) but phagocytosis of Klebsiella pneumoniae was unaltered even at high concentrations of the drug. Since roxithromycin displays the highest intracellular uptake, compared with the other macrolides assessed in this study, this could explain the results observed here. The relevance to the clinical situation needs further study. This effect of roxithromycin could be useful to control the inflammatory process associated in certain infectious diseases, in particular if high concentrations of the drug are obtained in tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559072     DOI: 10.1093/jac/24.4.561

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

Review 1.  The anti-inflammatory effects of macrolides.

Authors:  D Wales; M Woodhead
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  Can J Infect Dis       Date:  1992-07

3.  Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Authors:  Shigeki Nakamura; Yurika Ikeda-Dantsuji; Lianjin Jin; Yoshitsugu Higashi; Masahiro Abe; Tatsuya Inukai; Minoru Nagi; Makoto Urai; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Effect of monodesethyl amodiaquine on human polymorphonuclear neutrophil functions in vitro.

Authors:  M T Labro; J el Benna
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 5.  Effects of anti-infectious agents on polymorphonuclear neutrophils.

Authors:  M T Labro; J el Benna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 6.  Immunomodulation by antibacterial agents. Is it clinically relevant?

Authors:  M T Labro
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

7.  Effect of dirithromycin on Haemophilus influenzae infection of the respiratory mucosa.

Authors:  A Rutman; R Dowling; P Wills; C Feldman; P J Cole; R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro.

Authors:  E Sato; D K Nelson; S Koyama; J C Hoyt; R A Robbins
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 9.  Phagocyte uptake and transport of azithromycin.

Authors:  P J McDonald; H Pruul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

10.  Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role.

Authors:  C Agen; R Danesi; C Blandizzi; M Costa; B Stacchini; P Favini; M Del Tacca
Journal:  Agents Actions       Date:  1993-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.